Clinical trials: Disorder of Upper Gastrointestinal Tract
GERD
Esomeprazole for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs
This study is a randomised, double-blind, parallel-group and placebo controlled study comparing the efficacy of esomeprazole 40 mg orally qd vs. placebo and esomeprazole 20 mg orally qd vs.
- Trial name
- NCT00241540
- Testing
- Esomeprazole
- Where
- 119 sites in United States, Belgium and 4 more
- Volunteers
- 808 people
- Sponsor
- AstraZeneca
Gastrointestinal Diseases
DIAMANTE - Diseases Infectious Analysis Microflora Antibiotic Effect
To assess the effects of Bacillus clausii (Enterogermina®) on fecal microbial flora (using Polymerase Chain Reaction - Denaturing Gradient Gel Electrophoresis - PCR-DGGE - Method) in antibiotic-treated children with complicated…
- Trial name
- NCT00424905
- Testing
- Bacillus clausii
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Sanofi
Upper Gastrointestinal Symptoms
Comparative Study of MCCE With/Without Tether vs Conventional Upper Endoscopy in Patients With Upper Abdominal Symptoms
A prospective single blinded, tandem study, comparing a magnetically controlled capsule with or without a tether (MCC or MCC-T) with conventional upper endoscopy for the diagnosis of patients with upper abdominal symptoms.
- Trial name
- NCT04605302
- Testing
- MCC/MCC-T, Standard gastroscopy
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- AnX Robotica Corp.
Acute Coronary Syndrome, Myocardial Infarction
Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)
The purpose of the COGENT-1 clinical trial is to determine whether CGT-2168 (clopidogrel and omeprazole) compared to clopidogrel is safe and effective in reducing the incidence of gastrointestinal bleeding and symptomatic ulcer…
- Conditions
- Acute Coronary Syndrome, Myocardial Infarction, Coronary Artery Disease, Percutaneous Coronary Intervention
- Trial name
- COGENT-1 (NCT00557921)
- Testing
- CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin, Plavix (clopidogrel 75 mg) and aspirin
- Where
- 491 sites in United States, Australia and 14 more
- Volunteers
- 5,000 people
- Sponsor
- Cogentus Pharmaceuticals
Upper Gastrointestinal Bleeding (UGIB)
Evaluation of ClearPlasma in Patients With Upper Gastrointestinal Bleeding.
Upper gastrointestinal hemorrhage (UGIH) is one of the most common gastrointestinal emergencies, and is associated with significant morbidity and mortality. Plas-Free aims to evaluate ClearPlasma safety in patients with UGIH.
- Trial name
- CLearPlasma (NCT06761430)
- Testing
- ClearPlasma
- Where
- Italy
- Volunteers
- 7 people
- Sponsor
- PlasFree Ltd.
Upper Gastrointestinal Cancer
Real-World Use of Nivolumab for the Treatment of Patients With Metastatic Upper Gastrointestinal Cancer in Canada
The purpose of this observational study is to describe the demographics, and disease characteristics of participants with metastatic upper gastrointestinal cancer, along with the treatment characteristics of these patients when…
- Trial name
- NCT06361576
- Testing
- Nivolumab
- Where
- Canada
- Volunteers
- 700 people
- Sponsor
- Bristol-Myers Squibb
Leakage After Esophagectomy, Leakage After Gastrectomy
Eso-Sponge Registry
This international, prospective and multicenter registry was designed to collect clinical evidence for the endoscopic vacuum treatment using Eso-SPONGE® for anastomotic leakage after esophageal resection or iatrogenic or…
- Conditions
- Leakage After Esophagectomy, Leakage After Gastrectomy, Perforation of the Esophagus
- Trial name
- NCT02662777
- Testing
- Eso-SPONGE® vacuum treatment
- Where
- 17 sites in Germany
- Volunteers
- 108 people
- Sponsor
- Aesculap AG
Peptic Ulcer
Study to Assess the Efficacy and Safety of Somatostatin in the Treatment of Acute Severe Upper Gastrointestinal Bleeding
To assess the efficacy and safety of the early administration of somatostatin in infusion during 72 hours plus 2 boluses, compared to placebo in the control of acute severe UGIB with suspicion of PUB.
- Trial name
- NCT00152399
- Testing
- Somatostatin UCB (drug)
- Where
- 22 sites in Belgium, France and 4 more
- Volunteers
- 370 people
- Sponsor
- UCB Pharma